May 14, 2019
SymBio Pharmaceuticals Limited
(Securities Code: 4582)
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

# Notice Concerning Non-operating Expenses

SymBio Pharmaceuticals Limited ("the Company") announces accrued non-operating expenses for the first quarter of the fiscal year ending December 31, 2019 (from January 1, 2019 to March 31, 2019).

1. Details of Non-operating Expenses

   The Company recorded a foreign exchange loss of 16,807 thousand yen under non-operating expenses for the first quarter of the fiscal year ending December 31, 2019 (from January 1, 2019 to March 31, 2019) due to recent fluctuations in foreign exchange rates.

2. Future Outlook

   Based on its assumption concerning operational trends for this fiscal year, the Company determined that this non-operating expense would have no significant impact on the results of operations for the year with no modification to the financial forecast required. The Company will make a prompt announcement should any modification to the financial forecast be necessary.

**[Contact]**
Investor Relations
Tel: +81(0)3 5472 1125